PUBLIC COMPANY
saveTranscend Therapeutics Inc
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
- phase3An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
- phase3An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD
- phase2A Study to Assess the Use of Methylone in the Treatment of PTSD
- phase2An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD
- phase2An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD
- phase1A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects
🐶 Hiring Signal
News
- ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veteransThe U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).fiercebiotech · 5d ago
- Delix raises $100M to advance at-home psychedelic without hallucinogenic effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 7d ago
- Delix raises $100M to advance at-home psychedelic without hallucinatory effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 7d ago
- Update: Compass submits psilocybin depression drug for approval after stock wobblesCompass Pathways has completed an FDA filing for COMP360, with an expected launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilo…biospace · 8d ago
- BioSpace 40 Under 40 winners make their mark on biopharma40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-fron…biospace · 1mo ago
- As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safetyAs the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously…fiercebiotech · 2mo ago
- Psychedelic therapies ride wave of public favor into FDA hearingHeading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…biospace · 2mo ago
- Psilocybin proves promising in neuropathic pain mouse studyAmid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.fiercebiotech · 2mo ago
- Psychedelics on the cusp of market breakthrough as clinical, policy support growWhile there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.biospace · 3mo ago
- Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesEli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…biospace · 3mo ago
comments(0)
5-min edit window · permanent after that